LADENBURG THALM/SH SH started coverage on shares of CeriBell (NASDAQ:CBLL - Free Report) in a research note published on Friday, MarketBeat reports. The brokerage issued a buy rating and a $32.00 target price on the stock.
Several other research analysts also recently issued reports on CBLL. TD Cowen lifted their price objective on CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $32.50.
Get Our Latest Analysis on CBLL
CeriBell Trading Up 7.2 %
Shares of CBLL stock traded up $1.22 during midday trading on Friday, reaching $18.19. 81,881 shares of the company traded hands, compared to its average volume of 237,143. The business's 50 day moving average price is $21.61. CeriBell has a 1-year low of $16.59 and a 1-year high of $32.75.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to analyst estimates of $17.55 million. Sell-side analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.
Institutional Investors Weigh In On CeriBell
A number of hedge funds and other institutional investors have recently made changes to their positions in CBLL. Rhumbline Advisers boosted its stake in CeriBell by 26.5% in the 1st quarter. Rhumbline Advisers now owns 15,629 shares of the company's stock worth $300,000 after buying an additional 3,276 shares during the last quarter. Woodline Partners LP acquired a new position in CeriBell in the fourth quarter valued at $2,588,000. Yu Fan acquired a new stake in CeriBell during the fourth quarter worth about $31,631,000. TPG GP A LLC purchased a new position in shares of CeriBell in the 4th quarter worth about $102,677,000. Finally, RTW Investments LP purchased a new stake in shares of CeriBell during the 4th quarter worth about $3,882,000.
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Read More
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
